SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Sexual HealthFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Bremelanotide

Also known as PT-141, bremelanotide, vyleesi · Wikipedia

PT-141 (bremelanotide, marketed as Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist derived from alpha-MSH and Melanotan-II. The FDA approved Vyleesi in June 2019 for the on-demand treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, the first centrally acting drug approved for this indication. Unlike PDE5 inhibitors that act peripherally on vasculature, bremelanotide engages central melanocortin pathways that modulate sexual desire and arousal. It is administered subcutaneously via autoinjector approximately 45 minutes before anticipated activity. Off-label and research use in men and across the gender spectrum is widespread but unapproved. Also known as: Bremelanotide; Vyleesi.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Bremelanotide is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) derived from alpha-melanocyte-stimulating hormone via the Melanotan-II scaffold. It is a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R; sexual-arousal effects are mediated principally through central MC4R activation in hypothalamic nuclei (medial preoptic area and paraventricular nucleus) that integrate sexual motivation circuitry [Vyleesi label, FDA 2019].

Bremelanotide is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) derived from alpha-melanocyte-stimulating hormone via the Melanotan-II scaffold. It is a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R; sexual-arousal effects are mediated principally through central MC4R activation in hypothalamic nuclei (medial preoptic area and paraventricular nucleus) that integrate sexual motivation circuitry [Vyleesi label, FDA 2019]. RECONNECT phase 3 studies (Kingsberg 2019) confirmed reproducible improvements in desire and reductions in distress in premenopausal HSDD [PMID 35230162]. MC1R co-activation explains the characteristic hyperpigmentation signal.

Pharmacokinetic properties

Half-life

~2.7 hours (terminal half-life ~ 4-19.5 hours depending on metric); Tmax ~1 hour after SC injection

Routes

subcutaneous · intranasal

Bioavailability

Approved Vyleesi formulation is subcutaneous autoinjector. Intranasal forms were developed in earlier trials but discontinued for SC due to BP elevations; intranasal is still common in unregulated research-chemical use.

Amino-acid sequence

Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH (cyclic heptapeptide)

Use & research dosing

Libido SupportSexual Function

FDA-labeled regimen (Vyleesi, research framing only): 1.75 mg subcutaneously via autoinjector into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Per label, no more than one dose in 24 hours and no more than 8 doses per month. Bremelanotide should be discontinued after 8 weeks if no improvement in symptoms is observed. Self-experimentation protocols outside the label commonly use 1-2 mg subcutaneously 30-60 minutes pre-activity; intranasal formulations were abandoned in development due to blood-pressure elevation.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Widely used off-label in men for erectile function and libido support, despite the approved indication being female-specific HSDD. Distinguished from the closely related Melanotan-2 by a defined GMP-manufactured Vyleesi formulation with a known safety boundary, though MC1R activation still drives pigmentation effects. The compound originated as a deliberate development of Melanotan-II for sexual indications after observed erectogenic effects in tanning trials. RECONNECT (NCT02333071/NCT02338960) provided the pivotal efficacy and safety data underlying the 2019 approval.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • contraindicated in uncontrolled hypertension and known cardiovascular disease (transient ~6 mmHg systolic BP rise post-dose)
  • nausea is very common (~40% incidence, often severe with first dose; pre-treat with antiemetic if needed)
  • flushing, injection-site reactions, and headache are common
  • focal hyperpigmentation of face, gingiva, and breasts via MC1R-mediated melanogenesis (may be persistent)
  • not indicated for postmenopausal women or men (label restricts to premenopausal HSDD)
  • avoid in pregnancy (pregnancy testing recommended before use per label)
  • additive hypotensive risk if combined with PDE5 inhibitors after BP rise resolves; not recommended same-day
  • discontinue after 8 weeks if no benefit

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/35230162/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/31893927/
  3. [03]https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
  4. [04]https://clinicaltrials.gov/study/NCT02333071

Facts verified

2026-05-25

Confidence

high

What this means

  • Vyleesi label is female-specific; off-label male use is common in research-chemical channels

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.